Aromatase Inhibitor for Prevention of Ovarian Hyperstimulation Syndrome(OHSS)

Aromatase Inhibitor for Prevention of Ovarian Hyperstimulation Syndrome(OHSS)

Ovarian hyperstimulation syndrome (OHSS) was first described by Muller in 1962. Since then this iatrogenically originated malady has been reported to afflict high numbers of women who are in infertility treatment. The most serious and potentially lethal complication of controlled ovarian hyperstimulation (COH) is a severe form of OHSS. The incidence of OHSS is 5%-10% of all ovarian hyperstimulation for assisted reproduction treatment. It is characterized by ovarian enlargement with multiple follicular development, intravascular volume depletion and haemoconcentration.